Overview
Solventum Q3 sales rise 0.7% yr/yr, beating analyst expectations
Adjusted EPS for Q3 beats consensus, reaching $1.50
Company launches Transform for the Future initiative for cost savings and growth
Outlook
Solventum expects full-year organic sales growth at high end of +2.0% to +3.0% range
Solventum increases full-year adjusted EPS outlook to $5.98 to $6.08
Solventum revises free cash flow forecast to $150 mln to $250 mln
Result Drivers
ORGANIC SALES GROWTH - Driven by positive performance in Dental Solutions and Health Information Systems segments
TARIFF IMPACT - Incremental tariffs led to lower gross margins and decreased operating income margin
TRANSFORM INITIATIVE - Launch of Transform for the Future to reshape cost structure and enhance efficiency
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 sales | Beat | $2.10 bln | $2.05 bln (10 Analysts) |
Q3 Adjusted EPS | Beat | $1.50 | $1.43 (11 Analysts) |
Q3 EPS | $7.22 | ||
Q3 Net Income | $1.27 bln |
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 5 "strong buy" or "buy", 9 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for Solventum Corp is $85.00, about 20.4% above its November 5 closing price of $67.69
The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 12 three months ago
Press Release: ID:nPn64WdzDa
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)